原发性胃肠道淋巴瘤的诊疗进展

Diagnosis and Treatment Progress of Primary Gastrointestinal Lymphoma

原发性胃肠道淋巴瘤(PGIL)的发生率远低于累及胃肠道的继发性淋巴瘤。PGIL最常见的病理类型为B细胞淋巴瘤,包括弥漫大B细胞淋巴瘤和边缘区淋巴瘤,而T细胞来源的PGIL相对少见。PGIL患者在治疗过程中发生胃肠道穿孔、梗阻、出血等并发症风险高,影响患者的生活质量及生存时间。目前针对PGIL的治疗数据和随机对照试验仍然有限,缺乏最佳治疗方案,尤其是T细胞来源的PGIL预后极差,是现阶段治疗的难点。PGIL的传统治疗方式包括手术治疗及其与放疗、化疗结合的综合治疗,靶向及免疫治疗也在近年有了长足发展,为PGIL的治疗带来了希望。

Primary gastrointestinal lymphoma(PGIL)has much lower incidence than secondary lymphoma that affects the gastrointestinal tract.The most common pathological type of PGIL is B-cell lymphoma,including diffuse large B-cell lymphoma and marginal zone lymphoma,while PGIL derived from T-cell is relatively rare.PGIL patients have a high risk of complications such as gastrointestinal perforation,obstruction,and bleeding during the treatment process,which affects their quality of life and survival time.At present,the treatment data and randomized controlled trials for PGIL are still limited,and there is a lack of optimal treatment plans,especially for PGIL derived from T cells,which has a very poor prognosis and is currently a difficult point in the treatment.The traditional treatment methods for PGIL include surgical treatment and comprehensive treatment combined with radiotherapy and chemotherapy.Targeted therapy and immunotherapy have also made significant progress in recent years,bringing hopes for the treatment of PGIL.